The role of complement in autoimmune disease
The complement system is a crucial component of innate immunity and a central effective system to fight infections, microbes and to maintain cellular integrity and tissue homeostasis. The activated complement system avoids invading of microorganisms and mediates the elimination of dead or modified self cells, but the over-activation may also damage host tissues. To prevent this, several complement regulators act as either facilitators or cofactors to control the spontaneously activated complement cascade. Any disturbance in this self-mediated balance can result in damage of tissues and in autoimmune disease. Therefore, insights into the mechanisms of complement regulation are critical for understanding disease pathology and accelerate the development of therapies for complement –associated diseases. The complement-related disease Membranoproliferative glomerulonephritis type II is caused by a defective surface activation of the glomerular basement membrane and accumulation of debris, which induces rare kidney disorder leads to mesangial cell proliferation and structural changes in glomerular capillary walls. MPGN is associated with inappropriate complement regulation, such as functional inactivation or absence of the regulator Factor H, the presence of autoantibodies against Factor H or to the C3 convertase. The goal of my project is to identify additional pathological identifications of MPGN, and I hypothesize that Factor H related proteins or C3 convertase components are relevant for pathology. They will update the current knowledge of such kinds of diseases and will define to the mechanisms of complement regulation.
(2018) FHR5 Binds to Laminins, Uses Separate C3b and Surface-Binding Sites, and Activates Complement on Malondialdehyde-Acetaldehyde Surfaces. J Immunol 200(7), 2280-2290.
(2017) Anaphylatoxins Activate Ca2+, Akt/PI3-Kinase, and FOXO1/FoxP3 in the Retinal Pigment Epithelium. Front Immunol 8, 703.
(2015) The role of complement in C3 glomerulopathy. Mol Immunol 67(1), 21-30.
(2011) Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 365(24), 2340-2342.
Start of PhD
March 1, 2010
November 14, 2014